On December 30, 2022, a grand opening ceremony of the 2nd China Biopharmaceutical Industry Innovation and Transformation Conference was held online. A great number of KOLs and experts from the government, industry, academia, research institutions, venture capitals, hospitals and media attended this important year-end event, where Academician Zixin Deng of Chinese Academy of Sciences, the president of China Biomedicine Industry Innovation and Transformation Alliance announced the winners of 2022 China Biopharmaceutical Industry Innovation Billboard. "Benchmark Award" was granted to Innolake Biopharm as "The Most Notable Emerging Enterprise in 2022". The "Benchmark Award" was established and screened by the expert panel with an innovative drug evaluation system. With the aim of standing in the forefront of world science and technology, and focusing on the national strategic demands, this award can help to empower innovation and promote value creation by leveraging a global perspective and China driving force.

As an emerging power in the field of innovative drug development, Innolake Biopharm has been continuously acknowledged and recognized by the industry, and it is the second time listed on the innovation billboard since the company founded at the end of 2020.